Literature DB >> 20583924

An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Thomas S Uldrick1, Victoria Wang, Deirdre O'Mahony, Karen Aleman, Kathleen M Wyvill, Vickie Marshall, Seth M Steinberg, Stefania Pittaluga, Irina Maric, Denise Whitby, Giovanna Tosato, Richard F Little, Robert Yarchoan.   

Abstract

BACKGROUND: Kaposi sarcoma-associated herpesvirus (KSHV) is the causal agent for Kaposi sarcoma (KS) and multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-infected patients. Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, and hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) and human IL-6 (hIL-6).
METHODS: We identified 6 HIV-infected patients with KS or serological evidence of KSHV infection who had severe inflammatory MCD-like symptoms but in whom we could not diagnose MCD, and we hypothesized that these symptoms resulted from vIL-6 overproduction. Serum vIL-6 levels were assessed in these 6 patients and compared with levels in 8 control patients with symptomatic KSHV-MCD and 32 control patients with KS. KSHV viral load, serum hIL-6 level, and human IL-10 level were also evaluated.
RESULTS: Patients with inflammatory MCD-like symptoms but without MCD had elevated vIL-6 levels, comparable with levels in patients with symptomatic KSHV-MCD, and had levels that were significantly greater than those in control patients with KS (P = .003). Elevated hIL-6, IL-10, and KSHV viral loads were also comparable to patients with symptomatic KSHV-MCD and significantly greater than those with KS.
CONCLUSIONS: A subset of patients with HIV and KSHV co-infection, but without MCD, can develop severe systemic inflammatory symptoms associated with elevated levels of KSHV vIL-6, IL-6, and KSHV viral loads. Excess lytic activation of KSHV, production of the lytic gene product vIL6, and associated immunologic dysregulation may underlie the pathophysiology of these symptoms. This IL-6-related inflammatory syndrome is important to consider in critically ill patients with HIV and KSHV co-infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583924      PMCID: PMC2946207          DOI: 10.1086/654798

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.

Authors:  Y Aoki; G Tosato; T W Fonville; S Pittaluga
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  A quantification of human cells using an ERV-3 real time PCR assay.

Authors:  C C Yuan; W Miley; D Waters
Journal:  J Virol Methods       Date:  2001-02       Impact factor: 2.014

3.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  C Parravicini; B Chandran; M Corbellino; E Berti; M Paulli; P S Moore; Y Chang
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication.

Authors:  J Chang; R Renne; D Dittmer; D Ganem
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

5.  Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.

Authors:  M Mercader; B Taddeo; J R Panella; B Chandran; B J Nickoloff; K E Foreman
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant.

Authors:  M Schwarz; P M Murphy
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

7.  Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders.

Authors:  Y Aoki; R Yarchoan; K Wyvill; S Okamoto ; R F Little; G Tosato
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

8.  High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients.

Authors:  E Oksenhendler; G Carcelain; Y Aoki; E Boulanger; A Maillard; J P Clauvel; F Agbalika
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

Review 9.  AIDS-related malignancies.

Authors:  Chris Boshoff; Robin Weiss
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

10.  Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain.

Authors:  Sílvia de Sanjosé; Vickie Marshall; Judit Solà; Virgilio Palacio; Rosa Almirall; James J Goedert; F Xavier Bosch; Denise Whitby
Journal:  Int J Cancer       Date:  2002-03-01       Impact factor: 7.396

View more
  125 in total

1.  Whole-Genome Sequencing of Kaposi's Sarcoma-Associated Herpesvirus from Zambian Kaposi's Sarcoma Biopsy Specimens Reveals Unique Viral Diversity.

Authors:  Landon N Olp; Adrien Jeanniard; Clemence Marimo; John T West; Charles Wood
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

Review 2.  Animal models of tumorigenic herpesviruses--an update.

Authors:  Dirk P Dittmer; Blossom Damania; Sang-Hoon Sin
Journal:  Curr Opin Virol       Date:  2015-10       Impact factor: 7.090

3.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

Review 4.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

5.  Kaposi's sarcoma-associated herpesvirus microRNA single-nucleotide polymorphisms identified in clinical samples can affect microRNA processing, level of expression, and silencing activity.

Authors:  Soo-Jin Han; Vickie Marshall; Eugene Barsov; Octavio Quiñones; Alex Ray; Nazzarena Labo; Matthew Trivett; David Ott; Rolf Renne; Denise Whitby
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

Review 6.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

Review 7.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

8.  Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis.

Authors:  Salum J Lidenge; For Yue Tso; Owen Ngalamika; John R Ngowi; Yasaman Mortazavi; Eun Hee Kwon; Danielle M Shea; Veenu Minhas; Julius Mwaiselage; Charles Wood; John T West
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

9.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.

Authors:  Sang-Hoon Sin; Sun Ah Kang; Yongbaek Kim; Anthony Eason; Kelly Tan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

10.  Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).

Authors:  Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2015-12-12       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.